ClariVest Asset Management LLC cut its holdings in Natus Medical Incorporated (NASDAQ:BABY) by 28.0% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 60,725 shares of the medical equipment provider’s stock after selling 23,568 shares during the period. ClariVest Asset Management LLC owned about 0.18% of Natus Medical worth $2,277,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of BABY. Vanguard Group Inc. raised its holdings in shares of Natus Medical by 4.8% in the first quarter. Vanguard Group Inc. now owns 2,274,870 shares of the medical equipment provider’s stock valued at $89,289,000 after purchasing an additional 105,008 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Natus Medical by 226.0% during the first quarter. Renaissance Technologies LLC now owns 149,294 shares of the medical equipment provider’s stock worth $5,860,000 after buying an additional 103,494 shares during the last quarter. BlackRock Inc. increased its holdings in Natus Medical by 137,510.8% during the first quarter. BlackRock Inc. now owns 4,124,195 shares of the medical equipment provider’s stock worth $161,874,000 after buying an additional 4,121,198 shares during the last quarter. Schwab Charles Investment Management Inc. increased its holdings in Natus Medical by 8.4% during the first quarter. Schwab Charles Investment Management Inc. now owns 195,165 shares of the medical equipment provider’s stock worth $7,661,000 after buying an additional 15,175 shares during the last quarter. Finally, State Street Corp increased its holdings in Natus Medical by 8.5% during the first quarter. State Street Corp now owns 810,658 shares of the medical equipment provider’s stock worth $31,823,000 after buying an additional 63,493 shares during the last quarter. Institutional investors own 96.06% of the company’s stock.

Natus Medical Incorporated (NASDAQ BABY) traded up $1.15 during mid-day trading on Tuesday, reaching $39.35. 247,700 shares of the company’s stock were exchanged, compared to its average volume of 392,796. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.36 and a current ratio of 4.21. Natus Medical Incorporated has a 1 year low of $31.65 and a 1 year high of $43.85. The company has a market capitalization of $1,190.00, a PE ratio of 24.65 and a beta of 0.89.

Natus Medical (NASDAQ:BABY) last released its quarterly earnings data on Wednesday, October 25th. The medical equipment provider reported $0.40 EPS for the quarter, topping the Zacks’ consensus estimate of $0.38 by $0.02. Natus Medical had a negative net margin of 0.62% and a positive return on equity of 12.06%. The firm had revenue of $122.60 million during the quarter, compared to analysts’ expectations of $122.41 million. During the same period in the previous year, the business posted $0.39 earnings per share. The company’s revenue for the quarter was up 34.9% compared to the same quarter last year. research analysts expect that Natus Medical Incorporated will post 1.74 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “ClariVest Asset Management LLC Sells 23,568 Shares of Natus Medical Incorporated (BABY)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://www.watchlistnews.com/clarivest-asset-management-llc-sells-23568-shares-of-natus-medical-incorporated-baby/1717814.html.

A number of brokerages recently weighed in on BABY. BidaskClub downgraded shares of Natus Medical from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Zacks Investment Research upgraded shares of Natus Medical from a “sell” rating to a “hold” rating in a report on Friday, September 22nd. Two analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $46.50.

In other news, VP Dong Chune Christopher Chung sold 12,642 shares of the business’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $42.91, for a total value of $542,468.22. Following the completion of the sale, the vice president now owns 141,414 shares of the company’s stock, valued at $6,068,074.74. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director William M. Moore sold 5,000 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $41.01, for a total transaction of $205,050.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 22,042 shares of company stock valued at $902,266. Company insiders own 5.50% of the company’s stock.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Institutional Ownership by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.